CureVac NV Stock Quote CVAC - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

3.72

Bid

3.52

Ask

3.85

Volume

333,730

3.60 Day's Range 3.74

2.215 52 Week Range 10.14

Market Cap

833.238M

Previous Close

3.64

Open

3.69

Last Trade

3.76

Last Trade Time

Financial Volume

$ 1,223,669

VWAP

3.6666

Average Volume (3m)

1,411,507

Shares Outstanding

223,988,675

Dividend Yield

PE Ratio

-3.22

Earnings Per Share (EPS)

-1.16

Revenue

61.71M

Net Profit

-260.17M

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-gen... CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.curevac.com

Headquarters

Tubingen, Deu

Founded

1970

CureVac NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CVAC. The last closing price for CureVac NV was $3.64. Over the last year, CureVac NV shares have traded in a share price range of $ 2.215 to $ 10.14.

CureVac NV currently has 223,988,675 shares outstanding. The market capitalization of CureVac NV is $815.32 million. CureVac NV has a price to earnings ratio (PE ratio) of -3.22.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 144 - Report of proposed sale of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.03	0.813008130081	3.69	3.83	3.52	650183	3.68297331	CS
4	0.32	9.41176470588	3.4	3.87	2.95	1358589	3.33185168	CS
12	0.84	29.1666666667	2.88	5.28	2.8	1411507	3.70149524	CS
26	0.05	1.36239782016	3.67	5.28	2.215	1065801	3.47589581	CS
52	-5.18	-58.202247191	8.9	10.14	2.215	908531	4.27335936	CS
156	-48.84	-92.9223744292	52.56	75.68	2.215	747124	14.01076349	CS
260	-81.27	-95.6230144723	84.99	133	2.215	821711	35.10215477	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	260.07k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.61M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M